Biologics as countermeasures for acute radiation syndrome: where are we now? - Wikidata - awgldk - TriplyDB

Biologics as countermeasures for acute radiation syndrome: where are we now?

Biologics as countermeasures for acute radiation syndrome: where are we now?

http://www.wikidata.org/entity/Q42687966

about

γ-Tocotrienol as a Promising Countermeasure for Acute Radiation Syndrome: Current Status The Toll-Like Receptor 5 Agonist Entolimod Mitigates Lethal Acute Radiation Syndrome in Non-Human Primates Medical countermeasures for unwanted CBRN exposures: part II radiological and nuclear threats with review of recent countermeasure patents Succinate ester derivative of δ-tocopherol enhances the protective effects against (60)Co γ-ray-induced hematopoietic injury through granulocyte colony-stimulating factor induction in mice THE POTENTIATION OF THE RADIOPROTECTIVE EFFICACY OF TWO MEDICAL COUNTERMEASURES, GAMMA-TOCOTRIENOL AND AMIFOSTINE, BY A COMBINATION PROPHYLACTIC MODALITY.Patents for Toll-like receptor ligands as radiation countermeasures for acute radiation syndrome Combined immunomodulator and antimicrobial therapy eliminates polymicrobial sepsis and modulates cytokine production in combined injured mice Use of biomarkers for assessing radiation injury and efficacy of countermeasures Personalized Radioproteomics: Identification of a Protein Biomarker Signature for Preemptive Rescue by Tocopherol Succinate in CD34(+) Irradiated Progenitor Cells Isolated from a Healthy Control Donor.The Toll-Like Receptor 2/6 Agonist, FSL-1 Lipopeptide, Therapeutically Mitigates Acute Radiation Syndrome.Modeling radiation injury-induced cell death and countermeasure drug responses in a human Gut-on-a-Chip.Organs-on-a-Chip Module: A Review from the Development and Applications Perspective

P2860

Q26751505-AB6EB5EF-8AD7-4E01-B90B-61ECBA1705DA Q28548012-106506C2-2209-4550-8DB2-FF70DB92BD90 Q28817576-A03689C4-BC4F-4BB4-924F-BF7FE5AE2398 Q28817753-1749C246-5142-4C9E-8B1B-A172532AA907 Q33728050-6C4403BF-4C9D-4B1A-BDA8-B0BDA61F9435 Q36357104-3A4868B7-FFE5-4BF9-A786-667B064ED69B Q36357204-25D25268-DF6C-49F8-9737-18D8E2C7C438 Q36519142-959172E3-1C7E-4EAA-B4F0-83CDD825AAE2 Q36802901-FE60F050-F029-474F-AA36-4DF82EEC03A3 Q47125123-34E4226C-7C20-4D41-8B30-6BA9769FE488 Q51419671-C6388FDA-2B8E-465C-8542-5F019973DE77 Q58716430-961F8C7C-6949-417C-BE4B-A6B0FE666759

P2860

Biologics as countermeasures for acute radiation syndrome: where are we now?

http://www.wikidata.org/entity/Q42687966

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Biologics as countermeasures for acute radiation syndrome: where are we now?

@en

Biologics as countermeasures for acute radiation syndrome: where are we now?

@nl

type

label

Biologics as countermeasures for acute radiation syndrome: where are we now?

@en

Biologics as countermeasures for acute radiation syndrome: where are we now?

@nl

prefLabel

Biologics as countermeasures for acute radiation syndrome: where are we now?

@en

Biologics as countermeasures for acute radiation syndrome: where are we now?

@nl

P1433

Q42687966-1E9116CD-512D-4614-AE73-9F5DCED9FEBE

P1476

Q42687966-4B82A84E-B74D-4D85-8A9A-8492A6C95875

P2093

Q42687966-554AF974-09DE-411B-8B42-834E528CFB00

Q42687966-C79EE6F1-77DC-4881-AA45-8ED95089080C

P2860

Q42687966-0C710A7F-AAB0-46C7-871D-925520CE372E

Q42687966-1136A42E-5B7F-4135-A88A-C1B85CBD078B

Q42687966-1D379B90-1EC3-45EF-A78A-24E6F039C43E

Q42687966-443574F7-CFFB-4CC9-991F-47A9DC257FA6

Q42687966-47F5001A-9415-4FAB-9289-0EE55F97FFFF

Q42687966-64CA853A-10F8-4B83-9AEC-E5907A68079D

Q42687966-71208068-C891-4F8C-9E52-9D6EEFA63E9A

Q42687966-85937592-83F9-4BE3-8835-E5E6EAE0FF2A

Q42687966-8CAFD795-2288-4D41-A5C8-6FC2422304CD

Q42687966-B1646CA0-E940-4602-B76A-8969B7C31A8D

P304

Q42687966-81CFC25E-A9AD-4B22-970C-E52F2DA86658

P31

Q42687966-42FBF8CC-30DF-4BDF-9C16-517BCBEFEA28

Q42687966-8820ee22-b718-49cb-93ec-d408e6521696

P356

Q42687966-842ED3BE-762C-4F22-93A0-04A9AF934EEF

P407

Q42687966-6FE77047-2C0E-4A3E-9582-6C64A8237B4E

P433

Q42687966-5E17F434-1D7F-40A9-B3D7-BF5D682EA8C3

P478

Q42687966-27B7AD06-90EE-4041-A36B-A4A5649589ED

P50

Q42687966-21771B3E-47BE-41A8-B3BF-68DBEED6501B

P577

Q42687966-01E14F8D-6359-4523-A484-78BB519BB51B

P5875

Q42687966-CDC97DC2-A852-4FCE-AC0E-A435988E0810

P698

Q42687966-E30471A8-5F50-4DB2-99AA-02B545615FBE

P932

Q42687966-056E4516-5E3D-4093-A916-A305AA760BA8

P356

14712598.2015.986453

P1433

Expert Opinion on Biological Therapy

P1476

Biologics as countermeasures for acute radiation syndrome: where are we now?

@en

P2093

Patricia L P Romaine

http://www.w3.org/2001/XMLSchema#string

Victoria L Newman

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of granulocyte colony-stimulating factor and interleukin-6 as candidate biomarkers of CBLB502 efficacy as a medical radiation countermeasure

Single administration of stem cell factor, FLT-3 ligand, megakaryocyte growth and development factor, and interleukin-3 in combination soon after irradiation prevents nonhuman primates from myelosuppression: long-term follow-up of hematopoiesis.

Effects of recombinant human interleukin 11 on thrombocytopenia and neutropenia in irradiated rhesus monkeys.

Filgrastim improves survival in lethally irradiated nonhuman primates

Randomized comparison of single dose of recombinant human IL-12 versus placebo for restoration of hematopoiesis and improved survival in rhesus monkeys exposed to lethal radiation.

An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models.

Radiation countermeasure agents: an update (2011-2014)

Anti-ceramide antibody prevents the radiation gastrointestinal syndrome in mice.

Insulin-like growth factor 1 mitigates hematopoietic toxicity after lethal total body irradiation.

First global consensus for evidence-based management of the hematopoietic syndrome resulting from exposure to ionizing radiation.

P304

465-471

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14712598.2015.986453

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-11-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

268632657

http://www.w3.org/2001/XMLSchema#string

P698

25416452

http://www.w3.org/2001/XMLSchema#string

P932

4720033

http://www.w3.org/2001/XMLSchema#string